Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus pembrolizumab in PSA persistence or biochemical recurrence after prostatectomy
DRKS00025948Phase 2Active, not recruiting
- Sponsor
- Universitätsklinikum Freiburg
- Start
- May 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in prostate cancer (PCa), sponsored by Universitätsklinikum Freiburg. Started May 2022; status: active, not recruiting.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on DRKS00025948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00025948.